Update on novel agents in renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 9, Issue 12, 2009, Pages 1817-1827

  Tamaskar, Ila ^a   Pili, Roberto ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

c kit; HDAC; HIF ; Immunotherapy; Metastatic renal cell carcinoma; mTOR; PDGFR; Targeted therapy; VEGF receptor; VHL

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; AFLIBERCEPT; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANGIOPOIETIN RECEPTOR INHIBITOR; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; AXITINIB; BAY 73 4506; BEVACIZUMAB; C MET INHIBITOR; CYTOKINE; ENTINOSTAT; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; KRN 951; PANOBINOSTAT; PAZOPANIB; PERIFOSINE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VORINOSTAT;

ADVANCED CANCER; ANOREXIA; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTHRALGIA; ASTHENIA; BLADDER CANCER; BLEEDING; BOLUS INJECTION; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHONIA; DYSPHORIA; EXFOLIATIVE DERMATITIS; FATIGUE; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY FAILURE; LEIOMYOSARCOMA; LUNG EMBOLISM; MACULOPAPULAR RASH; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PNEUMONIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOLID TUMOR; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UTERUS SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 73349107447     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.157     Document Type: Review

References (58)

1. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 335, 865-875 (1996).
3. Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J. Pathol. 183, 131-133 (1997).
4. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHLindependent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22, 200-209 (1998).
5. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993).
6. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90 (1994).
7. Gallou C, Joly D, Mejean A et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13, 464-475 (1999).
8. Schraml P, Struckmann K, Hatz F et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J. Pathol. 196, 186-193 (2002).
9. Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700-9704 (1994).
10. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991-5004 (2004). Review of pathogenesis of clear-cell carcinoma of the kidney.
11. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 270, 13333-13340 (1995).
12. Maher ER, Kaelin WG Jr. Von Hippel-Lindau disease. Medicine (Baltimore) 76, 381-391 (1997).
13. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003).
14. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007). This study compares the efficacy of tyrosine kinase inhibitors versus IFN-a and placed sunitinib in the front-line setting for treatment of metastatic renal cell carcinoma (RCC).
15. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007). Trial of first mTOR inhibitor in poor-risk and all pathological subtypes of RCC.
16. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
17. Kasid U, Dritschilo A. RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 22, 5876-5884 (2003).
18. Moore M, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of the novel raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann. Oncol. 16, 1688-1694 (2005).
19. Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92, 1855-1861 (2005).
20. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11, 5472-5480 (2005).
21. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965-972 (2005).
22. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006).
23. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007). Pivotal Phase III trial confirming sorafenib's significant progression-free survival benefit and acceptable tolerability in patients with advanced refractory RCC. These findings formed the basis of sorafenib's US FDA approval for this indication.
24. Tamaskar I, Bukowski R, Elson P et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol. 19, 265-268 (2008).
25. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
26. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006).
27. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 99, 81-83 (2007).
28. Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26, 5204-5212 (2008).
29. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019 (2007).
30. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
31. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon a-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370, 2103-2111 (2007). This study reported the data that led the FDA to approve the use of bevacizumab in RCC.
32. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon a compared with interferon a monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422-5428 (2008).
33. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918 (2004).
34. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008). This study provides the evidence for the use of everolimus following tyrosine kinase inhibitors.
35. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol. 8, 975-984 (2007). Phase II study showing efficacy of this novel VEGF receptor inhibitor in the second-line setting.
36. Kumar R, Harrington LE, Hopper TM et al. Correlation of anti-tumor and antiangiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice. Proceedings of the American Society of Clinical Oncology 23 (2005) (Abstract 9537).
37. Hutson TE, Davis ID, Machiels JH, et al. Biomarker analysis and final efficacy and safety results of a Phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. J. Clin. Oncol. 26, (2008) (Abstract 5046). Early evidence for the clinical activity of pazopanib in RCC.
38. Sternberg CN, Szczylik C, Lee E et al. A randomized, double-blind Phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 27, 15s (2009) (Abstract 5021).
39. Verheul HM, Hammers H, van Erp K et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin. Cancer Res. 13, 4201-4208 (2007).
40. Dupont J, Schwartz L, Koutcher J et al. Phase I and pharmacokinetic study of VEGF trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. 22, 3009 (2004).
41. Bhargava P, Esteves B, Lipatov ON et al. Activity and safety of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC): interim results of a Phase II randomized discontinuation trial. Presented at: 2009 Genitourinary Cancers Symposium Orlando, FL, USA 26-28 Feburary 2009 (Abstract 283).
42. Eisen T, Joensuu H, Nathan P et al. Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer. J. Clin. Oncol. 27, 15s (2009) (Abstract 5033).
43. Tannir N, Wong Y, Kollmannsberger C et al. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: efficacy and safety results. J. Clin. Oncol. 27, 15s (2009) (Abstract 5036).
44. Qian DZ, Kato Y, Shabbeer S et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 12, 634-642 (2006).
45. Qian DZ, Wang X, Kachhap SK et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 64, 6626-6634 (2004).
46. Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68-73 (1997).
47. Eder JP, Appleman L, Heath E et al. A Phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs). J. Clin. Oncol. 24(18 Suppl.), 3041 (2006).
48. Ross RW, Stein M, Sarantopoulos J et al. A Phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC) 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 15601)
49. Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am. J. Pathol. 159, 2271-2280 (2001).
50. Gale NW, Thurston G, Hackett SF et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell 3, 411-423 (2002).
51. Currie MJ, Gunningham SP, Turner K et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J. Pathol. 198, 502-510 (2002).
52. Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25, 2369-2376 (2007).
53. Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 27(27), 4462-4468 (2009).
54. Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol. 182, 29-34 (2009).
55. Whorf RC, Hainsworth JD, Spigel DR et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J. Clin. Oncol. 26(20 Suppl.), (2008) (Abstract 5010).
56. Atkins MB, Ernstoff MS, Figlin RA et al. Innovations and challenges in renal cell carcinoma: summary statement from the second Cambridge conference. Clin. Cancer Res. 13, 667s-670s (2007).
57. Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26, 3709-3714 (2008).
58. Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1432-1439 (2009).